The original success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but betting in companies primarily reliant on generic versions presents a challenging picture. While early earnings were impressive, the cessation of patents and the emergence of cheaper alternatives have weakened market share. Consequently, a thorough assess